Follow last change Sep 2026 re-read 3 minutes ago

G207

Developed for: glioblastoma · anaplastic astrocytoma · malignant glioma · astrocytoma (excluding glioblastoma) · cancer of cerebellum · cerebellar astrocytoma · cerebral primitive neuroectodermal tumor · childhood central nervous system primitive neuroectodermal neoplasm
+5 more
· epithelial neoplasm · giant cell glioblastoma · medulloblastoma · metastatic neoplasm · primitive neuroectodermal tumor
Investigated by: Cannonball Kids' Cancer Foundation · M.D. Anderson Cancer Center · MediGene · National Cancer Institute (NCI) · Treovir, Inc · American Lebanese Syrian Associated Charities
+18 more
· Battle for a Cure Foundation · Eli Jackson Foundation · Eli's Block Party Childhood Cancer Foundation · Food and Drug Administration (FDA) · Gregory K. Friedman, MD · Hyundai Hope On Wheels · Jaxon's F.R.O.G. Foundation · Kaul Pediatric Research Institute · Kelsie's Crew · Memorial Sloan Kettering Cancer Center · National Center for Advancing Translational Sciences (NCATS) · Pediatric Brain Tumor Consortium · Rally Foundation for Childhood Cancer Research · Sandcastle Kids · St. Baldrick's Foundation · The Andrew McDonough B+ Foundation · United States Department of Defense · University of Alabama at Birmingham

200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028202920302031

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 13 trials
Phase 1	NCT03911388	Sep 2019 → Sep 2026 overdue	cancer of cerebellum, cerebellar astrocytoma, childhood central nervous system primitive neuroectodermal neoplasm, epithelial neoplasm +4	M.D. Anderson Cancer Center	Recruiting	No outcome recorded
Phase 1	NCT02457845	May 2016 → Jun 2020	anaplastic astrocytoma, cerebral primitive neuroectodermal tumor, glioblastoma, primitive neuroectodermal tumor	Gregory K. Friedman, MD	Completed	No outcome recorded
Phase 1	NCT00157703	May 2005 → Oct 2008	malignant glioma	MediGene	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT00028158	Dec 2001 → Oct 2003	astrocytoma (excluding glioblastoma), glioblastoma	MediGene	Completed	No outcome recorded
Phase 22 trials
Phase 2	NCT07649070	Nov 2026 → Dec 2030 expected	malignant glioma	M.D. Anderson Cancer Center	Not yet recruiting	No outcome recorded
Phase 2	NCT04482933	Sep → Dec 2025	anaplastic astrocytoma, giant cell glioblastoma	Pediatric Brain Tumor Consortium	Withdrawn	No outcome recorded Stop: Enrollment

Date	Issuer	Release
2021-04-12	Treovir, Inc	Results Treovir Announces Positive Results of Phase 1 Study of G207 in Pediatric Patients with Recurrent High-Grade Glioma treovir.com ↗ G207 showed evidence of radiographic, neuropathological, or clinical response in 11 of 12 patients
2020-08-04	Treovir, Inc	Regulatory G207 Fast Track Designation treovir.com ↗ Treovir announces today that G207 has been granted Fast Track Designation by the US FDA for treatment of recurrent high-grade gliomas in children.
2019-05-09	Treovir, Inc	Regulatory G207 Orphan Designation treovir.com ↗ Treovir announces that G207 has been awarded Orphan Drug designation by the US FDA for treatment of medulloblastoma (DRU-2019-824) and primitive neuroectodermal brain tumor (PNET) (DRU-2019-6922).

Date	Issuer	Release
2024-12-06	Treovir, Inc	Treovir announces opening of G207 Phase 2 clinical trial in children with recurrent brain tumors. treovir.com ↗
2021-04-12	Treovir, Inc	Treovir Announces Positive Results of Phase 1 Study of G207 in Pediatric Patients with Recurrent High-Grade Glioma treovir.com ↗
2020-09-01	Treovir, Inc	Treovir Awarded Phase 2 SBIR Grant to Support G207 Clinical Development treovir.com ↗
2020-08-04	Treovir, Inc	G207 Fast Track Designation treovir.com ↗
2019-12-24	Treovir, Inc	Treovir Announces G207 Acquisition treovir.com ↗
2019-05-09	Treovir, Inc	G207 Orphan Designation treovir.com ↗

Every value below carries the sentence it was read from. 7 sources stand behind the page.

Field	Value	Cited text
Known as	G207	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03911388 ↗ 5 NCT04482933 ↗ NCT00157703 ↗ NCT02457845 ↗ NCT07649070 ↗ NCT00028158 ↗
Known as	Experimental: HSV G207	“Experimental: HSV G207” NCT04482933 ↗
Known as	HSV G207	“HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors” NCT02457845 ↗
Known as	HSV-1 (G207)	“Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI” NCT04482933 ↗
Modality	Other / unclassified	“G207 (an experimental virus therapy)” NCT03911388 ↗
Route	Other	“stereotactic intratumoral administration” PMID 24572293 ↗ Feb 2014